TrendingVideosIndia
Opinions | CommentEditorialsThe MiddleLetters to the EditorReflections
UPSC | Exam ScheduleExam Mentor
State | Himachal PradeshPunjabJammu & KashmirHaryanaChhattisgarhMadhya PradeshRajasthanUttarakhandUttar Pradesh
City | ChandigarhAmritsarJalandharLudhianaDelhiPatialaBathindaShaharnama
World | ChinaUnited StatesPakistan
Diaspora
Features | The Tribune ScienceTime CapsuleSpectrumIn-DepthTravelFood
Business | My MoneyAutoZone
News Columns | Straight DriveCanada CallingLondon LetterKashmir AngleJammu JournalInside the CapitalHimachal CallingHill View
Don't Miss
Advertisement

Israel reports very few myocarditis cases among 12-15 year olds after booster

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits
Yearly Premium ₹999 ₹349/Year
Yearly Premium $49 $24.99/Year
Advertisement

Jerusalem, January 5

Advertisement

Only two cases of myocarditis were reported in Israel among 44,000 youngsters aged 12 to 15 who received a third dose of the Pfizer/BioNtech vaccine, the Health Ministry said on Wednesday.

Advertisement

The heart inflammations developed by two male teens were both mild, the ministry said.

Studies have shown that while the Pfizer/BioNTech COVID-19 vaccine marginally increases the risk of heart inflammation, the risk is higher among those infected with the coronavirus. Israel has played a leading role in studying the effects of COVID-19 vaccines, as the fastest country to roll out two-dose inoculations to a wide population a year ago and one of the first to give third shots as boosters.

It is now administering fourth doses to people over 60, health workers and immunocompromised patients.

Advertisement

The data is being watched closely by other countries, including the United States, where the US Food and Drug Administration on Monday authorised the use of a third dose of the Pfizer and BioNTech COVID-19 vaccine for 12-15-year-olds.

An advisory panel to the U.S. Centers for Disease Control and Prevention (CDC) is due to meet on Wednesday to discuss boosters for that age group. Reuters

Advertisement
Show comments
Advertisement